Evidence map›Paper›PMID 35008270›Full record

ArticleCancers2021

Identification of Neoantigens in Two Murine Gastric Cancer Cell Lines Leading to the Neoantigen-Based Immunotherapy.

Koji Nagaoka, Changbo Sun, Yukari Kobayashi, Takayuki Kanaseki, Serina Tokita, Toshihiro Komatsu, Kazuhiro Maejima, Junichiro Futami, Sachiyo Nomura, Keiko Udaka and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Neoantigen mRNA vaccines induce progenitor-exhausted T cells that support anti-PD-1 therapy in gastric cancer with peritoneal metastasis.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025
    Article
  5. Article
  6. Neoantigen immunotherapy: a novel treatment for bladder cancer.Exploration of targeted anti-tumor therapy · 2025
    Review
  7. Janus kinase inhibitor overcomes resistance to immune checkpoint inhibitor treatment in peritoneal dissemination of gastric cancer in C57BL/6 J mice.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024
    Article
  8. Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Koji NagaokaDepartment of Immunotherapeutics, The University of Tokyo Hospital, Tokyo 113-8655, Japan.ORCID 0000-0001-8202-031X
Changbo SunDepartment of Immunotherapeutics, The University of Tokyo Hospital, Tokyo 113-8655, Japan.
Yukari KobayashiDepartment of Immunotherapeutics, The University of Tokyo Hospital, Tokyo 113-8655, Japan.ORCID 0000-0002-2600-2181
Takayuki KanasekiDepartment of Pathology, Sapporo Medical University, Sapporo 060-8556, Japan.
Serina TokitaDepartment of Pathology, Sapporo Medical University, Sapporo 060-8556, Japan.
Toshihiro KomatsuDepartment of Immunology, Kochi University, Kochi 783-8505, Japan.
Kazuhiro MaejimaRIKEN Center for Integrative Medical Sciences, Laboratory for Cancer Genomics, Yokohama 230-0045, Japan.
Junichiro FutamiDepartment of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama 700-8530, Japan.ORCID 0000-0002-0020-2855
Sachiyo NomuraDepartment of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.ORCID 0000-0003-4293-6205
Keiko UdakaDepartment of Immunology, Kochi University, Kochi 783-8505, Japan.
Hidewaki NakagawaRIKEN Center for Integrative Medical Sciences, Laboratory for Cancer Genomics, Yokohama 230-0045, Japan.ORCID 0000-0003-1807-772X
Toshihiko TorigoeDepartment of Pathology, Sapporo Medical University, Sapporo 060-8556, Japan.ORCID 0000-0002-9463-5917
Kazuhiro KakimiDepartment of Immunotherapeutics, The University of Tokyo Hospital, Tokyo 113-8655, Japan.ORCID 0000-0003-2631-3040
University of Tokyo Hospital · JPSapporo Medical University · JPRIKEN Center for Integrative Medical Sciences · JPUniversity of Kochi · JPOkayama University · JPThe University of Tokyo · JP

Funding

Japan Agency for Medical Research and Development JP 19cm0106552Japan Agency for Medical Research and Development JP 21ck0106639Japan Society for the Promotion of Science 20K09161
6 · The paper itself

Abstract

To develop combination immunotherapies for gastric cancers, immunologically well-characterized preclinical models are crucial. Here, we leveraged two transplantable murine gastric cancer cell lines, YTN2 and YTN16, derived from the same parental line but differing in their susceptibility to immune rejection. We established their differential sensitivity to immune checkpoint inhibitors (ICI) and identified neoantigens. Although anti-CTLA-4 mAbs eradicated YTN16 tumors in 4 of 5 mice, anti-PD-1 and anti-PD-L1 mAbs failed to eradicate YTN16 tumors. Using whole-exome and RNA sequencing, we identified two and three neoantigens in YTN2 and YTN16, respectively. MHC class I ligandome analysis detected the expression of only one of these neoantigens, mutated Cdt1, but the exact length of MHC binding peptide was determined. Dendritic cell vaccine loaded with neoepitope peptides and adoptive transfer of neoantigen-specific CD8

Indexed as

adoptive cell therapy (ACT)checkpoint inhibitorDC vaccinegastric cancerneoantigen

Identifiers

PMID35008270
PMCPMC8750027
OpenAlexW4200107130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.